Phase II Study of Denosumab to Define the Role of Bone Related Biomarkers in Breast Cancer Bone Metastasis
Latest Information Update: 07 Nov 2021
At a glance
- Drugs Denosumab (Primary)
- Indications Bone metastases; Breast cancer; Carcinoma
- Focus Biomarker; Pharmacodynamics
- 05 Nov 2019 Status changed from completed to discontinued.
- 22 Mar 2019 Status changed from active, no longer recruiting to completed.
- 25 Jan 2018 Planned End Date changed from 1 Feb 2020 to 1 Feb 2021.